HelixBind’s sepsis test gets breakthrough device designation from FDA
Category: #headline  By Mateen Dalal  Date: 2020-08-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

HelixBind’s sepsis test gets breakthrough device designation from FDA

HelixBind Inc., the U.S-based biotechnology company focused on the diagnosis and management of bloodstream infection, has reportedly received breakthrough device designation from the US FDA (Food and Drug Administration) for its RaPID Sepsis testing method named ‘RaPID/BSI’

According to sources familiar with knowledge of the matter, the company has developed the RaPID/BSI test to identify the ‘most common’ bloodstream infections associated with sepsis. RaPID is a direct-from-blood platform designed to characterize and detect bloodstream infections.

Sepsis is the outcome of a huge immune response to a bacterial infection that grows into the blood. Around 1.7million cases are reportedly in America, while more than 27,000 people die from sepsis each year. The condition frequently leads to organ failure. It is a medical emergency that becomes life-changing and fatal for most of the individuals who develop this “blood poisoning.”

Precise and rapid identification of the infection is important to assist doctors to begin the required antimicrobial treatment. HelixBind said in the statement that RaPID/BSI detects bloodstream infections within hours, while current testing methods take several days. The new solutions also help doctors to choose appropriate antimicrobial treatment for patients.

The new testing method covers a large panel of 21 bacterial as well as fungal pathogens and has high sensitivity to detect small concentrations of pathogens present within blood specimens.

Speaking on the new testing method, Alon Singer, Chief Executive Officer at HelixBind said that the company is thrilled to secure the breakthrough device designation from US FDA and it is a strong validation of the company’s work.

Mr. Singer added that the company is looking forward to being in touch with the USA FDA and follow the agency’s guidance to ensure RaPID/BSI is effective and safe, significantly enhancing the lives of countless individuals who are suffering from a sepsis infection.

Source Credit - https://www.medicaldevice-network.com/news/helixbind-breakthrough-device-designation-sepsis-test/

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

Novartis reveals data from Phase III COMBI-i trial for melanoma
Novartis reveals data from Phase III COMBI-i trial for melanoma
By Mateen Dalal

Swiss-based multinational pharmaceutical company, Novartis has recently revealed detailed results fr...

Curevo declares antibody response data from Phase 1 study of CRV-101
Curevo declares antibody response data from Phase 1 study of CRV-101
By Mateen Dalal

Biopharmaceutical major, Curevo Vaccine, has reportedly announced the release of antibody response d...

CATO SMS announces acquisition of Wilmington-based Array Biostatistics
CATO SMS announces acquisition of Wilmington-based Array Biostatistics
By Mateen Dalal

CATO SMS, one of the leading providers of specialized clinical research solutions, has reportedly ac...